Auristatin PE is primarily used in the field of targeted cancer therapy. It is a potent cytotoxic agent that is often conjugated to monoclonal antibodies to form antibody-drug conjugates (ADCs). These ADCs are designed to specifically target and deliver the cytotoxic payload to cancer cells, minimizing damage to healthy tissues. The application of Auristatin PE in ADCs allows for the precise delivery of the drug to tumor cells, where it inhibits cell division by disrupting microtubule dynamics. This leads to cell cycle arrest and ultimately induces apoptosis in the cancer cells. Its high potency makes it particularly effective in treating various types of cancers, including lymphoma, leukemia, and solid tumors. Auristatin PE is a key component in the development of novel cancer therapies, offering a more targeted approach compared to traditional chemotherapy. Its use in ADCs represents a significant advancement in oncology, providing hope for improved outcomes and reduced side effects for cancer patients.